

Resource Summary Report

Generated by [RRID](#) on Aug 30, 2026

[NCI-N87/TR](#)

RRID:CVCL_IL03

Type: Cell Line

Proper Citation

RRID:CVCL_IL03

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_IL03

Proper Citation: RRID:CVCL_IL03

Description: Cell line NCI-N87/TR is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Gastric tubular adenocarcinoma

Defining Citation: [PMID:26108989](#)

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NCI-N87/TR

Cross References: cancercellines:CVCL_IL03, Wikidata:Q54908218

ID: CVCL_IL03

Hierarchy: cvcl_1603

Record Creation Time: 20220427T220841+0000

Record Last Update: 20260829T234744+0000

Ratings and Alerts

No rating or validation information has been found for NCI-N87/TR.

No alerts have been found for NCI-N87/TR.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Liang B, et al. (2024) Cdc42-driven endosomal cholesterol transport promotes collateral resistance in HER2-positive gastric cancer. Cancer letters, 587, 216702.

Hu X, et al. (2023) Glutamine metabolic microenvironment drives M2 macrophage polarization to mediate trastuzumab resistance in HER2-positive gastric cancer. Cancer communications (London, England), 43(8), 909.

Wang J, et al. (2022) Disrupting Circadian Rhythm via the PER1-HK2 Axis Reverses Trastuzumab Resistance in Gastric Cancer. Cancer research, 82(8), 1503.

McCombs JR, et al. (2021) Antibody-drug conjugate and free geldanamycin combination therapy enhances anti-cancer efficacy. International journal of pharmaceuticals, 610, 121272.